SMAD3 reportedly supports the growth of prostate cancer cells under hypoxic conditions [21], further supporting the notion that hypoxic adaptation may represent an important oncogenic function of ONECUT2 and its target genes SMAD3 and EPAS1 in BPDCN. This evidence concerns the gene SMAD3 and prostate cancer.